Intra-Cellular Therapies Inc (ITCI)
66.53
-0.31
(-0.46%)
USD |
NASDAQ |
May 16, 16:00
66.56
+0.03
(+0.05%)
After-Hours: 20:00
Intra-Cellular Therapies Cash from Financing (Quarterly): 9.989M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.989M |
| December 31, 2023 | 3.004M |
| September 30, 2023 | 2.581M |
| June 30, 2023 | 8.585M |
| March 31, 2023 | 3.64M |
| December 31, 2022 | 2.187M |
| September 30, 2022 | 5.654M |
| June 30, 2022 | 5.504M |
| March 31, 2022 | 441.81M |
| December 31, 2021 | 7.914M |
| September 30, 2021 | 0.591M |
| June 30, 2021 | 1.582M |
| March 31, 2021 | 1.432M |
| December 31, 2020 | 3.635M |
| September 30, 2020 | 378.49M |
| June 30, 2020 | 4.480M |
| March 31, 2020 | 277.57M |
| December 31, 2019 | 2.793M |
| September 30, 2019 | 0.1524M |
| June 30, 2019 | 0.2592M |
| March 31, 2019 | 0.0312M |
| Date | Value |
|---|---|
| December 31, 2018 | 0.1859M |
| September 30, 2018 | 0.1554M |
| June 30, 2018 | 0.0061M |
| March 31, 2018 | 0.3378M |
| December 31, 2017 | 162.13M |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.0066M |
| March 31, 2017 | 0.2242M |
| December 31, 2016 | -124.97M |
| September 30, 2016 | 125.10M |
| June 30, 2016 | 0.1844M |
| March 31, 2016 | 0.1637M |
| December 31, 2015 | 0.3244M |
| September 30, 2015 | 327.50M |
| June 30, 2015 | 0.174M |
| March 31, 2015 | 121.89M |
| December 31, 2014 | 0.0639M |
| September 30, 2014 | 0.029M |
| June 30, 2014 | 0.1694M |
| March 31, 2014 | 115.45M |
| June 30, 2013 | 0.0059M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.1524M
Minimum
Sep 2019
441.81M
Maximum
Mar 2022
58.09M
Average
3.638M
Median
Cash from Financing (Quarterly) Benchmarks
| Johnson & Johnson | 546.00M |
| Insmed Inc | 3.022M |
| Madrigal Pharmaceuticals Inc | 573.71M |
| Vertex Pharmaceuticals Inc | -357.50M |
| Fate Therapeutics Inc | 95.49M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -34.12M |
| Cash from Investing (Quarterly) | 16.18M |
| Free Cash Flow | -98.25M |
| Free Cash Flow Per Share (Quarterly) | -0.3522 |
| Free Cash Flow to Equity (Quarterly) | -34.12M |
| Free Cash Flow to Firm (Quarterly) | -34.12M |
| Free Cash Flow Yield | -1.53% |